Boston Scientific

BSX

Market cap $133B

Boston Scientific Corporation (BSX) M&A Call Transcript

Boston Scientific Corp (NYSE:BSX, XETRA:BSX) announced a definitive agreement to acquire medical device company Penumbra (NYSE:PEN) in a cash and stock transaction valuing Penumbra at $374 per share, or approximately $14.5 billion in enterprise value. Penumbra shares rose almost 12% on the news to about $350, while Boston Scientific shares fell 4.5% to about $90.

BALA CYNWYD, Pa., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.

Boston Scientific stock may rebound after agreeing to buy Valencia Technologies, adding the FDA-approved eCoin ITNS device to expand its Urology portfolio.

Boston Scientific on Thursday announced plans to acquire Penumbra, a US-based thrombectomy specialist, in a cash-and-stock deal valued at about $14.5 billion, marking one of the largest transactions in the global medical technology sector this year.

The cash-and-stock acquisition values Penumbra at $374 a share.

Penumbra's stock was up about 14% after the deal was announced Thursday morning.

Boston Scientific will buy Penumbra for $14.5 billion, or $374 a share, expanding its cardiovascular reach. Penumbra stock jumped.

Boston Scientific has agreed to buy thrombectomy company Penumbra for about $15 billion in cash and stock in a deal that bolsters its cardiovascular portfolio.

Boston Scientific said on Thursday it will buy Penumbra in a deal valued at about $14.5 billion.